Annexin Pharmaceuticals AB (ST:ANNX) — Market Cap & Net Worth
Market Cap & Net Worth: Annexin Pharmaceuticals AB (ANNX)
Annexin Pharmaceuticals AB (ST:ANNX) has a market capitalization of $9.23 Million (Skr85.77 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27237 globally and #597 in its home market, demonstrating a -6.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Annexin Pharmaceuticals AB's stock price Skr12.15 by its total outstanding shares 7059096 (7.06 Million). Review ANNX liabilities breakdown to assess the company's total debt and financial obligations.
Annexin Pharmaceuticals AB Market Cap History: 2017 to 2026
Annexin Pharmaceuticals AB's market capitalization history from 2017 to 2026. Data shows growth from $2.95 Million to $9.23 Million (7.13% CAGR).
Index Memberships
Annexin Pharmaceuticals AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.84 Billion | 0.06% | #163 of 281 |
Weight: Annexin Pharmaceuticals AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Annexin Pharmaceuticals AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Annexin Pharmaceuticals AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANNX by Market Capitalization
Companies near Annexin Pharmaceuticals AB in the global market cap rankings as of June 19, 2026.
Key companies related to Annexin Pharmaceuticals AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Annexin Pharmaceuticals AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Annexin Pharmaceuticals AB's market cap moved from $2.95 Million to $ 9.23 Million, with a yearly change of 7.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr9.23 Million | -38.64% |
| 2025 | Skr15.04 Million | +4472.75% |
| 2024 | Skr328.94K | +66.54% |
| 2023 | Skr197.51K | -73.95% |
| 2022 | Skr758.15K | -0.20% |
| 2021 | Skr759.67K | -43.50% |
| 2020 | Skr1.34 Million | +51.76% |
| 2019 | Skr886.00K | +3.53% |
| 2018 | Skr855.77K | -70.94% |
| 2017 | Skr2.95 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Annexin Pharmaceuticals AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.23 Million USD |
| MoneyControl | $9.23 Million USD |
| MarketWatch | $9.23 Million USD |
| marketcap.company | $9.23 Million USD |
| Reuters | $9.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmo… Read more